Global Trends in Oliceridine (TRV130) Research from 2013 to 2024: A Bibliometrics and Knowledge Graph Analysis
Cong Wang,Lidan Liu,Xue Bai
DOI: https://doi.org/10.2147/dddt.s475205
IF: 4.3188
2024-10-22
Drug Design Development and Therapy
Abstract:Cong Wang, 1 Lidan Liu, 1 Xue Bai 2 1 Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People's Republic of China; 2 Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People's Republic of China Correspondence: Xue Bai, Department of Health Management, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110004, People's Republic of China, Email Purpose: The adverse effects and drug abuse issues associated with opioid drugs have made finding a safe and effective alternative a focus of research. Oliceridine has attracted attention for its lower adverse reactions, such as respiratory depression and gastrointestinal issues, compared to traditional opioids, and is considered a promising candidate for addressing the current limitations in opioid therapy. This article explored the knowledge structure of oliceridine through bibliometric analysis, highlighting its clinical applications in managing acute pain and its mechanisms that may reduce addiction risk. Our bibliometric analysis highlighted hotspots and trends in oliceridine research, guiding future studies on its safety and efficacy in pain management. Methods: This study utilized the Web of Science Core Collection database to search for articles related to oliceridine from 2013 to 2024. Systematic analysis was conducted on publication, country, institution, author, journal, references, and keywords. The software Citespace, Vosviewer, and Bibliometrix were employed to visualize bibliometric analysis. Results: From 2013 to 2024, 159 articles on oliceridine were published in 98 journals by 158 institutions from 28 countries. The United States has rapidly developed in this field, providing significant momentum. Keyword clustering analysis revealed that research on oliceridine primarily focused on exploring its molecular and pharmacological mechanisms and conducting clinical studies to evaluate its efficacy and safety in pain management. Analyses of the strongest citation bursts with references and keywords indicated that protein-biased ligands and oliceridine were hotspots. The emergence of divergent views regarding oliceridine's biased agonism will lead to future hotspots focusing on the underlying mechanisms of biased signaling by G protein-coupled receptors and drug design. Conclusion: Bibliometric analysis provides insights into the current hotspots and emerging areas of oliceridine, which can guide future research. The widespread attention and clinical application of oliceridine lay a solid foundation for further drug development and clinical trials. Keywords: opioid receptors, biased agonism, oliceridine, bibliometrics Pain represents a global public health issue, with opioid medications considered the primary choice for effective pain relief. However, adverse reactions associated with opioid drugs can limit their optimal analgesic dosage. These adverse reactions decrease patient compliance and reduce their quality of life. Moreover, the abuse of opioid drugs is a significant social problem. Therefore, the objective of opioid analgesic drug development has consistently been to create μ-opioid receptor agonists with high affinity and specificity. The μ-opioid receptor belongs to the G protein-coupled receptor family, which is a cell surface receptor that binds to extracellular substances and transmits intracellular signals through G proteins. 1 The interaction of opioid drugs with the μ-opioid receptor triggers signaling through the G protein and the β-arrestin pathways. Stimulation of the G protein pathway produces analgesic effects. In contrast, activation of the β-arrestin pathway is associated with opioid-related adverse events. 2 The focus on biased agonism is crucial because it allows for the selective activation of the G protein pathway while minimizing β-arrestin activation. This differentiation has the potential to separate therapeutic benefits from harmful side effects, leading to safer pain management options and a reduced risk of opioid-related complications. In attempts to reduce side effects, an increasingly exciting area is the design of opioid drugs that activate one pathway rather than another. 3–8 Bohn and colleagues found that morphine maintained its analgesic efficacy without tolerance in β-arrestin 2 gene knockout animals, which subsequently led to the development of TRV130. 9,10 TRV130 is a novel G protein-biased μ-opioid receptor agonist. It activates G protein signaling while causing minimal recruitment of β-arrestin proteins. 3 Trevena led the development of TRV130, later -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal